Biomarkers in tear fluid of dupilumab‐treated moderate‐to‐severe atopic dermatitis patients-Reference-Cited by-同舟云学术

Biomarkers in tear fluid of dupilumab‐treated moderate‐to‐severe atopic dermatitis patients

Published:2022-12-22 Issue:2 Volume:53 Page:239-243
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Experimental Allergy

Author:

Achten Roselie¹^ORCID,Thijs Judith¹^ORCID,van Luijk Chantal²^ORCID,Knol Edward¹³^ORCID,Delemarre Eveline³^ORCID,de Graaf Marlies¹^ORCID,Bakker Daphne¹^ORCID,de Boer Joke²^ORCID,van Wijk Femke³^ORCID,de Bruin‐Weller Marjolein¹^ORCID

Affiliation:

1. Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands

2. Department of Ophthalmology University Medical Center Utrecht Utrecht The Netherlands

3. Center for Translational Immunology University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

Funder

Sanofi Genzyme

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cea.14269

Reference9 articles.

1. Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study